Shares of Mednax, Inc (NYSE:MD) have earned an average rating of “Hold” from the fourteen analysts that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has issued a buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $57.43.

Several analysts recently issued reports on MD shares. TheStreet lowered Mednax from a “b-” rating to a “c+” rating in a report on Tuesday, May 16th. Stifel Nicolaus cut their price objective on Mednax from $65.00 to $58.00 and set a “hold” rating for the company in a report on Thursday, May 25th. Mizuho cut their price objective on Mednax from $64.00 to $58.00 and set a “neutral” rating for the company in a report on Tuesday, May 30th. ValuEngine lowered Mednax from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BidaskClub upgraded Mednax from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 13th.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another site, it was stolen and reposted in violation of US and international trademark & copyright law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/08/mednax-inc-md-receives-57-43-average-pt-from-analysts.html.

Mednax (MD) traded up 0.77% during midday trading on Tuesday, reaching $41.95. The company’s stock had a trading volume of 320,284 shares. The firm has a market capitalization of $3.87 billion, a price-to-earnings ratio of 13.36 and a beta of 0.40. Mednax has a 12 month low of $41.20 and a 12 month high of $72.13. The stock’s 50-day moving average price is $46.00 and its 200-day moving average price is $58.11.

Mednax (NYSE:MD) last announced its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.81 by $0.04. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business had revenue of $843 million during the quarter, compared to analyst estimates of $849.49 million. During the same period last year, the company earned $1.03 earnings per share. Mednax’s quarterly revenue was up 9.2% compared to the same quarter last year. Analysts predict that Mednax will post $3.31 EPS for the current year.

In other Mednax news, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The stock was sold at an average price of $57.57, for a total transaction of $113,355.33. Following the transaction, the director now directly owns 18,072 shares in the company, valued at $1,040,405.04. The transaction was disclosed in a filing with the SEC, which is available through this link. 2.40% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Eagle Boston Investment Management Inc. raised its holdings in Mednax by 12.9% during the second quarter. Eagle Boston Investment Management Inc. now owns 191,636 shares of the company’s stock valued at $11,569,000 after buying an additional 21,895 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in Mednax by 55.2% during the first quarter. JPMorgan Chase & Co. now owns 79,610 shares of the company’s stock valued at $5,524,000 after buying an additional 28,301 shares in the last quarter. Mn Services Vermogensbeheer B.V. grew its position in shares of Mednax by 527.2% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 15,228 shares of the company’s stock valued at $919,000 after purchasing an additional 12,800 shares during the last quarter. Prudential Financial Inc. grew its position in shares of Mednax by 7.9% in the first quarter. Prudential Financial Inc. now owns 58,520 shares of the company’s stock valued at $4,060,000 after purchasing an additional 4,270 shares during the last quarter. Finally, Achmea Investment Management B.V. acquired a new stake in shares of Mednax in the first quarter valued at about $966,000.

Mednax Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Analyst Recommendations for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.